Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Am J Psychiatry. 2023 Jul 12;180(9):685–698. doi: 10.1176/appi.ajp.20220304

Table 1: Demographic characteristics for all participants in the study.

CNV chromosomal coordinates are provided in megabase (Mb) with the number of genes encompassed in each CNV and a well-known gene for each locus, to help recognize the CNV. Clinically ascertained participants come from five cohorts and non-clinically ascertained participants are from the UK Biobank. Age range, mean and standard deviation (SD), as well as sex (Male/Female) are reported for clinical and non-clinical participants separately.

Diagnoses column reports the number of participants with ASD, SZ, and other diagnoses including the following list: language disorder, major depressive disorder, post traumatic stress disorder (PTSD), unspecified disruptive and impulse-control and conduct disorder, social anxiety disorder, social phobia disorder, speech sound disorder, moderate intellectual disability, specific learning disorder, gambling disorder, bipolar disorder, conduct disorder, attention deficit/hyperactivity disorder ADHD, Substance abuse disorder, global developmental delay, motor disorder, obsessive compulsive disorder, sleep disorder, Tourette’s disorder, mood disorder, eating disorders, transient tic disorder, trichotillomania, pervasive developmental disorder NOS, specific phobia, body dysmorphic disorder, mathematics disorder, dysthymic disorder.

IQ loss (in IQ-points) and odds ratio (OR) for autism spectrum disorder and schizophrenia risk were extracted from previous publications (3, 51). Detailed demographics are reported in Table ST1.

Loci start-stop coordinates Type nGenes Gene Ascertainment N Age Age Sex Diagnoses IQ loss OR ASD/SZ
(hg19) Mb (cohorts) range mean (SD) M/F ASD/SZ/other
1q21.1 chr1 146.53–147.39 Del 7 CHDIL Clinical (BC, CDF, EU, SVIP) 28 8–73 29 (18) 17/11 1 / 0 / 7 15 3.2/6.4
Non-clinical (UKB) 12 47–68 59 (7) 5/7 0 / 1 / 3
Dup Clinical (BC, CDF, EU, SVIP) 17 8–65 35 (17) 9/8 1 / 0 / 4 25 5.3/2.9
Non-clinical (UKB) 13 51–72 62 (6) 9/4 -

TAR chr1 145.39–145.81 Dup 15 RBM8 Non-clinical (UKB) 31 48–74 60 (8) 14/17 - 2.4 -

13q12.12 chr13 23.56–24.88 Dup 5 SPATA13 Non-clinical (UKB) 21 50–76 62 (8) 11/10 - 0.6 -

15q11.2 chr15 22.81–23.09 Del 4 CYF1P1 Non-clinical (UKB) 108 49–78 65 (7) 59/49 0 / 0 / 2 5.7 1.3/1.9
Dup Non-clinical (UKB) 144 46–79 64 (7) 77/67 0 / 0 / 6 0.9 1.8/1

16p11.2 chr16 29.65–30.20 Del 27 KCTD13 Clinical (BC, CDF, EU, SVIP) 78 6–54 17 (11) 36/42 - 26 14.3/1.1
Non-clinical (UKB) 4 63–70 66 (3) 1/3 -
Dup Clinical (BC, CDF, EU, SVIP) 68 8–63 31 (15) 29/39 10 / 1 / 19 11 10.5/11.7
Non-clinical (UKB) 7 53–69 65 (6) 3/4 -

16p13.11 chr16 15.51–16.29 Dup 6 NDE1 Non-clinical (UKB) 50 51–78 66 (6) 26/24 - 8.7 1.5/2

22q11.2 chr22 19.04–21.47 Del 49 AIFM3 Clinical (BC, CDF, UCLA) 68 6–35 14 (6) 33/35 8 / 2 / 31 28.8 32.3/23
Dup Clinical (BC, CDF, UCLA) 19 6–45 17 (13) 6/13 2 / 0 / 8 8.3 2/0.2
Non-clinical (UKB) 7 48–80 60 (11) 5/2 0 / 0 / 1

Controls - Clinical (BC, CDF, EU, SVIP, UCLA) 317 6–63 26 (14) 142/175 1 / 0 / 23 - -
Non-clinical (UKB) 465 47–80 64 (7) 245/220 -

Abbreviations, Del: deletion; Dup: duplication; BC: Brain-Canada (University of Montreal); CDF: Cardiff University; EU: the 16p11.2 European Consortium; UKB: UK Biobank; SVIP: the Simons Variation in Individuals Project; ASD: autism spectrum disorder; SZ: schizophrenia; OR: Odds ratio; IQ: intelligence quotient; chr: chromosome; M: male; F: female; Age: mean age; SD: standard deviation; nGenes: number of genes encompassed by the CNV.